Online inquiry

IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6072MR)

This product GTTS-WQ6072MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCL2 gene. The antibody can be applied in Pulmonary Fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002982.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6347
UniProt ID P13500
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6072MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13232MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ6592MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ13976MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ4077MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ3031MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ859MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ7115MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ9183MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW